$Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation$

Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation

Saved in:

Bibliographic Details
Main Authors:	Pronamee Borah, Ayoniza Maitri, Rahul Naithani
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137924003274
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
by: Xuelian Jin, et al.
Published: (2025-01-01)

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia
by: Yu Zhang, et al.
Published: (2025-02-01)

Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
by: Kopmar NE, et al.
Published: (2024-11-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Construction of a five-gene-based prognostic model for relapsed/refractory acute lymphoblastic leukemia
by: Bi Zhou, et al.
Published: (2024-12-01)

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
by: Andrew D. Hughes, et al.
Published: (2025-01-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study
by: Muhit Özcan, et al.
Published: (2025-01-01)

Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia
by: Athanasios Tragiannidis, et al.
Published: (2024-09-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
by: Julia M. Unglaub, et al.
Published: (2025-01-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Relapsed Acute Lymphoblastic Leukemia Presenting as Acute Renal Failure
by: Ashley Rose, et al.
Published: (2019-01-01)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
by: Brandi Anders, et al.
Published: (2017-01-01)

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation
by: Emiko Kashima, et al.
Published: (2024-12-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

Isolated peripheral neuroleukemiosis mimicking Guillain‐Barré syndrome in an adolescent with relapsed B‐lymphoblastic leukemia
by: Ethan Edmondson, et al.
Published: (2024-12-01)

A Unique Case of Relapsed B-Acute Lymphoblastic Leukemia/Lymphoma as an Isolated Omental Mass
by: Kanchan Kantekure, et al.
Published: (2014-01-01)

Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
by: Maike Breidenbach, et al.
Published: (2025-01-01)

Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review
by: Salimah Valliani, et al.
Published: (2020-01-01)

Value of routine blood count surveillance in detecting relapse in acute lymphoblastic leukemia
by: Sarah AlHarbi, et al.
Published: (2025-01-01)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
by: Lauren Elreda, et al.
Published: (2014-01-01)

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia
by: Xinping Cao, et al.
Published: (2025-01-01)

Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
by: Jin Yin, et al.
Published: (2024-12-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
by: Jorge E. Cortes, et al.
Published: (2025-01-01)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
by: Stephen E. Langabeer, et al.
Published: (2016-01-01)

Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
by: Yi Xiao, et al.
Published: (2020-05-01)

Plasma-based transcriptomic non-coding signature for predicting relapse in pediatric acute lymphoblastic leukemia
by: Yaping Wang, et al.
Published: (2024-12-01)

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases
by: Ingolf Molle, et al.
Published: (2022-01-01)

Fate of children after the first relapse of acute lymphoblastic leukemia: InPOG-ALL-19-02 study
by: Pritam Singha Roy, et al.
Published: (2024-01-01)

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
by: Kristian A. Choate, et al.
Published: (2024-10-01)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
by: Mehmet Akce, et al.
Published: (2016-01-01)

Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
by: Yan Wu, et al.
Published: (2024-11-01)

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials
by: Zelin Cai, et al.
Published: (2024-11-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)